Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six‐month, randomized, placebo‐controlled, double‐blind clinical trial

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

(2018) Erin A. Bohula et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

(2018) Erin A Bohula et al.   LANCET

Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitus

(2017) Faidon Magkos et al.   Obesity

Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate With Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical Trial

(2016) Olivia M. Farr et al.   DIABETES

5-HT2C Receptor Agonist Anorectic Efficacy Potentiated by 5-HT1B Receptor Agonist Coapplication: An Effect Mediated via Increased Proportion of Pro-Opiomelanocortin Neurons Activated

(2013) B. Doslikova et al.   JOURNAL OF NEUROSCIENCE

Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study

(2012) Patrick M. O'Neil et al.   Obesity

A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial

(2011) Meredith C. Fidler et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

(2010) Steven R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

HDL particle size and the risk of coronary heart disease in apparently healthy men and women: The EPIC-Norfolk prospective population study

(2009) Benoit J. Arsenault et al.   ATHEROSCLEROSIS